List of Velcade drug patents

Velcade is owned by Takeda Pharms Usa.

Velcade contains Bortezomib.

Velcade has a total of 4 drug patents out of which 4 drug patents have expired.

Expired drug patents of Velcade are:

  • US6713446*PED
  • US6958319*PED
  • US6958319
  • US6713446

Velcade was authorised for market use on 13 May, 2003.

Velcade is available in injectable;intravenous, subcutaneous dosage forms.

The generics of Velcade are possible to be released after 25 July, 2022.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6958319 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(1 year, 2 days ago)

US6713446 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(1 year, 2 days ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6713446

(Pediatric)

TAKEDA PHARMS USA Formulation of boronic acid compounds
Jul, 2022

(6 months ago)

US6958319

(Pediatric)

TAKEDA PHARMS USA Formulation of boronic acid compounds
Jul, 2022

(6 months ago)

Exclusivity Exclusivity Expiration
Pediatric Exclusivity (PED) Apr 8, 2022

Drugs and Companies using BORTEZOMIB ingredient

Market Authorisation Date: 13 May, 2003

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

How can I launch a generic of VELCADE before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in